| PATENT REGISTER | |||||||||||||||||||||
| A Supplementary Protection Certificate (SPC) exists for this Patent. To view the SPC Details click following SPC number(s): 2016/025 2016/036 | |||||||||||||||||||||
| Status | Granted | Patent No. | 2215124 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Application No. | 08798550.3 | Date of Filing | 22/08/2008 | ||||||||||||||||||
| Date Grant Published | 24/02/2016 | Application Published | 11/08/2010 | ||||||||||||||||||
| Title of Invention | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) | ||||||||||||||||||||
| Priority |
|
||||||||||||||||||||
| Inventors |
JACKSON, Simon, Mark WALKER, Nigel Pelham, Clinton PIPER, Derek, Evan SHAN, Bei SHEN, Wenyan CHAN, Joyce Chi, Yee KING, Chadwick, Terence KETCHEM, Randal, Robert MEHLIN, Christopher CARABEO, Teresa, Arazas CAO, Qiong |
||||||||||||||||||||
| Current Proprietor |
Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 UNITED STATES OF AMERICA |
||||||||||||||||||||
| Address for service |
VALIPAT S.R.L. Uitbreidingstraat 72 - 5 2600 Antwerp BELGIUM |
||||||||||||||||||||
| Renewal Fees |
|
||||||||||||||||||||
| Publication Language | English | ||||||||||||||||||||
| Translation Received Date | |||||||||||||||||||||
| 25/02/2016 | Divisional Application number: 13151343.4 Date of receipt: 15/01/2013 | ||||||||||||||||||||
| 25/02/2016 | Divisional Application number: 13151352.5 Date of receipt: 15/01/2013 | ||||||||||||||||||||
| 25/02/2016 | Divisional Application number: 13151375.6 Date of receipt: 15/01/2013 | ||||||||||||||||||||
| 25/02/2016 | Divisional Application number: 13151377.2 Date of receipt: 15/01/2013 | ||||||||||||||||||||
| 25/02/2016 | Divisional Application number: 13151381.4 Date of receipt: 15/01/2013 | ||||||||||||||||||||
| 25/02/2016 | Divisional Application number: 15202482.4 Date of receipt: 23/12/2015 | ||||||||||||||||||||
| 13/04/2016 | Address for Service recorded as VALIPAT S.A., Rue de Livourne, 7, B-1060 BRUSSELS, Belgium received on 11/04/2016. | ||||||||||||||||||||
| 09/06/2016 | Request for grant a Supplementary Protection Certificate, citing Patent number 2215124 as the relevant basic patent, in respect of the product Evolocumab filed on 02/06/2016. Reference number of request is 2016/025. | ||||||||||||||||||||
| 24/08/2016 | Request for grant a Supplementary Protection Certificate, citing Patent number 2215124 as the relevant basic patent, in respect of the product Alirocumab filed on 23/08/2016. Reference number of request is 2016/036. | ||||||||||||||||||||
| 16/11/2020 | Request for grant of Supplementary Protection Certificate No. 2016/036 withdrawn on 16/11/2020. | ||||||||||||||||||||
| 02/03/2021 | Supplementary Protection Certificate Number 2016/025, having an expiry date of 20/07/2030 granted on 02/03/2021. | ||||||||||||||||||||
| 30/08/2021 | Change of Address for Service from VALIPAT S.A., Rue de Livourne, 7, B-1060 BRUSSELS, Belgium to VALIPAT S.R.L., Uitbreidingstraat 72 - 5, 2600 Antwerp, Belgium recorded on 18/08/2021 | ||||||||||||||||||||
| 04/04/2023 | Application for an extension of the duration of Supplementary Protection Certificate No. 2016/025 filed on 03/04/2023. | ||||||||||||||||||||
| 20/07/2023 | Amendment of patent specification as a result of opposition proceedings at the EPO on 19/07/2023 | ||||||||||||||||||||
| 28/12/2023 | Correction of Patent Specification on 27/12/2023 (B9) | ||||||||||||||||||||
